Ambroxol Demonstrates Safety and Neuroprotection Signals in Parkinson’s Dementia Trial

Results published in JAMA Neurology show that phase 2 biomarker preservation alongside stable cognitive and psychiatric measures supports a larger, cognition-focused Ambroxol study later this year.